Adco-Lamivudine Solution

Indication

Treatment of HIV-1 infection in combination with other antiretroviral agents.

Dosage (summary)

The recommended dose for adults and children over 12 years is 300 mg once daily or 150 mg twice daily. For children aged 3 months to 12 years, the dose is based on body weight.

Onset of Action / Duration

Antiviral effects may be observed within 2 to 4 weeks of therapy initiation.

Special Populations

• Renal impairment
• Hepatic impairment
• Elderly patients

Pregnancy & Breastfeeding

Lamivudine is classified as Category C. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk; therefore, breastfeeding is not recommended during treatment.

Key Drug Interactions

• Zidovudine may increase the risk of hematologic toxicity when used with lamivudine.
• Co-administration with other antiretroviral agents should be done with caution.

Contraindications

• Hypersensitivity to lamivudine or any component of the formulation.
• Severe hepatic impairment.

Common side effects

• Headache
• Nausea
• Fatigue
• Diarrhea
• Liver enzyme elevation

Counselling Points

• Adherence to the prescribed regimen is crucial for treatment efficacy.
• Inform patients about the importance of regular follow-up and monitoring.
• Advise patients to report any signs of liver problems, such as jaundice or dark urine.